These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 8112406)

  • 21. The use of the xanthine oxidase inhibitor, allopurinol, in the control of hyperuricaemia, gout and uric acid calculi.
    Emmerson BT
    Australas Ann Med; 1967 Aug; 16(3):205-14. PubMed ID: 6056609
    [No Abstract]   [Full Text] [Related]  

  • 22. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
    Takai M; Yamauchi T; Ookura M; Matsuda Y; Tai K; Kishi S; Yoshida A; Iwasaki H; Nakamura T; Ueda T
    Anticancer Res; 2014 Dec; 34(12):7287-96. PubMed ID: 25503162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
    Bruce SP
    Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
    Grabowski B; Khosravan R; Wu JT; Vernillet L; Lademacher C
    Br J Clin Pharmacol; 2010 Jul; 70(1):57-64. PubMed ID: 20642548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors.
    Ishibuchi S; Morimoto H; Oe T; Ikebe T; Inoue H; Fukunari A; Kamezawa M; Yamada I; Naka Y
    Bioorg Med Chem Lett; 2001 Apr; 11(7):879-82. PubMed ID: 11294382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Febuxostat for the treatment of gout.
    Bridgeman MB; Chavez B
    Expert Opin Pharmacother; 2015 Feb; 16(3):395-8. PubMed ID: 25556668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aesculin possesses potent hypouricemic action in rodents but is devoid of xanthine oxidase/dehydrogenase inhibitory activity.
    Kong L; Zhou J; Wen Y; Li J; Cheng CH
    Planta Med; 2002 Feb; 68(2):175-8. PubMed ID: 11859475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Febuxostat efficacy in allopurinol-resistant tophaceous gout.
    Uh M; Reid G
    J Clin Rheumatol; 2011 Jun; 17(4):204-6. PubMed ID: 21617552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longan seed extract reduces hyperuricemia via modulating urate transporters and suppressing xanthine oxidase activity.
    Hou CW; Lee YC; Hung HF; Fu HW; Jeng KC
    Am J Chin Med; 2012; 40(5):979-91. PubMed ID: 22928829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Administration of procyanidins from grape seeds reduces serum uric acid levels and decreases hepatic xanthine dehydrogenase/oxidase activities in oxonate-treated mice.
    Wang Y; Zhu JX; Kong LD; Yang C; Cheng CH; Zhang X
    Basic Clin Pharmacol Toxicol; 2004 May; 94(5):232-7. PubMed ID: 15125693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro xanthine oxidase inhibitory and in vivo hypouricemic activity of herbal coded formulation (Gouticin).
    Akram M; Usmanghani K; Ahmed I; Azhar I; Hamid A
    Pak J Pharm Sci; 2014 May; 27(3):541-50. PubMed ID: 24811815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Febuxostat for treatment of chronic gout.
    Gray CL; Walters-Smith NE
    Am J Health Syst Pharm; 2011 Mar; 68(5):389-98. PubMed ID: 21330679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Gout: an overview of available urate lowering therapies].
    Richette P
    Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of allopurinol on caffeine disposition in man.
    Grant DM; Tang BK; Campbell ME; Kalow W
    Br J Clin Pharmacol; 1986 Apr; 21(4):454-8. PubMed ID: 3754760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose.
    Carroll MB; Smith DM; Shaak TL
    Rheumatol Int; 2017 Mar; 37(3):445-453. PubMed ID: 27798726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
    Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
    Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
    Bomalaski JS; Clark MA
    Curr Rheumatol Rep; 2004 Jun; 6(3):240-7. PubMed ID: 15134605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.